Stemline Therapeutics, Inc. (STML) Forms $14.65 Double Top; Anthem, Inc. (ANTM) Had 13 Bullish Analysts

Stemline Therapeutics, Inc. (STML) formed double top with $15.82 target or 8.00% above today’s $14.65 share price. Stemline Therapeutics, Inc. (STML) has $370.45 million valuation. The stock decreased 3.62% or $0.55 during the last trading session, reaching $14.65. About 128,719 shares traded. Stemline Therapeutics, Inc. (NASDAQ:STML) has risen 52.65% since January 7, 2017 and is uptrending. It has outperformed by 35.95% the S&P500.

Among 24 analysts covering Anthem Inc (NYSE:ANTM), 13 have Buy rating, 0 Sell and 11 Hold. Therefore 54% are positive. Anthem Inc had 63 analyst reports since July 27, 2015 according to SRatingsIntel. The company was maintained on Friday, November 17 by Bank of America. As per Tuesday, November 15, the company rating was upgraded by Wells Fargo. The firm has “Hold” rating by Evercore given on Friday, September 23. As per Wednesday, June 7, the company rating was initiated by Morgan Stanley. The company was initiated on Thursday, June 16 by Bernstein. Citigroup initiated the shares of ANTM in report on Friday, October 2 with “Buy” rating. The stock has “Outperform” rating by RBC Capital Markets on Thursday, January 28. The rating was maintained by FBR Capital on Thursday, October 29 with “Mkt Perform”. Cantor Fitzgerald maintained Anthem, Inc. (NYSE:ANTM) on Monday, November 6 with “Buy” rating. The company was maintained on Tuesday, May 30 by RBC Capital Markets. See Anthem, Inc. (NYSE:ANTM) latest ratings:

03/01/2018 Broker: Goldman Sachs Rating: Hold New Target: $243.0 Initiate
03/01/2018 Broker: PiperJaffray Old Rating: Neutral New Rating: Overweight Old Target: $151 Upgrade
06/12/2017 Broker: FBR Capital Rating: Inc. 2.75
17/11/2017 Broker: Bank of America Rating: Buy Old Target: $249 New Target: $254 Maintain
07/11/2017 Broker: Leerink Swann Rating: Outperform Old Target: $245 New Target: $300 Maintain
06/11/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $226.0 Maintain
03/11/2017 Broker: Credit Suisse Rating: Buy New Target: $234.0 Initiate
25/10/2017 Broker: Jefferies Rating: Hold New Target: $226.0 Maintain
26/10/2017 Broker: Morgan Stanley Rating: Equal-Weight Old Target: $201 New Target: $215 Maintain
25/10/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $220.0 Maintain

Investors sentiment increased to 1.24 in 2017 Q3. Its up 0.24, from 1 in 2017Q2. It improved, as 6 investors sold Stemline Therapeutics, Inc. shares while 19 reduced holdings. 13 funds opened positions while 18 raised stakes. 12.54 million shares or 4.36% more from 12.02 million shares in 2017Q2 were reported. Comml Bank Of Ny Mellon stated it has 0% of its portfolio in Stemline Therapeutics, Inc. (NASDAQ:STML). The Nebraska-based Ameritas Inv Inc has invested 0% in Stemline Therapeutics, Inc. (NASDAQ:STML). D E Shaw Com reported 87,294 shares stake. Victory Cap Mgmt Inc holds 0% of its portfolio in Stemline Therapeutics, Inc. (NASDAQ:STML) for 1,858 shares. Carl Domino invested 0.35% of its portfolio in Stemline Therapeutics, Inc. (NASDAQ:STML). Rhumbline Advisers stated it has 27,648 shares. Sphera Funds Mngmt Limited holds 0.48% or 300,000 shares in its portfolio. Baker Bros Lp stated it has 633,497 shares or 0.06% of all its holdings. Columbus Circle has invested 0.05% in Stemline Therapeutics, Inc. (NASDAQ:STML). Manufacturers Life The invested 0% in Stemline Therapeutics, Inc. (NASDAQ:STML). Fmr Ltd Liability Co owns 2.00 million shares. Bnp Paribas Arbitrage holds 0% in Stemline Therapeutics, Inc. (NASDAQ:STML) or 2,317 shares. Bailard Inc has invested 0.05% in Stemline Therapeutics, Inc. (NASDAQ:STML). Grp One Trading Ltd Partnership reported 0% of its portfolio in Stemline Therapeutics, Inc. (NASDAQ:STML). Farallon Capital Mgmt Lc holds 0.12% of its portfolio in Stemline Therapeutics, Inc. (NASDAQ:STML) for 1.19 million shares.

Analysts await Stemline Therapeutics, Inc. (NASDAQ:STML) to report earnings on March, 15. They expect $-0.67 EPS, down 19.64% or $0.11 from last year’s $-0.56 per share. After $-0.68 actual EPS reported by Stemline Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -1.47% EPS growth.

Since December 15, 2017, it had 0 insider purchases, and 1 insider sale for $169,942 activity. $169,942 worth of Stemline Therapeutics, Inc. (NASDAQ:STML) was sold by Hoberman Kenneth.

Among 4 analysts covering Stemline Therapeutics Inc (NASDAQ:STML), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Stemline Therapeutics Inc had 12 analyst reports since November 10, 2015 according to SRatingsIntel. H.C. Wainwright maintained the stock with “Buy” rating in Tuesday, September 12 report. The firm has “Buy” rating given on Monday, June 26 by Jefferies. H.C. Wainwright maintained Stemline Therapeutics, Inc. (NASDAQ:STML) on Friday, November 10 with “Buy” rating. The rating was maintained by H.C. Wainwright on Monday, June 26 with “Buy”. The firm earned “Buy” rating on Thursday, December 14 by H.C. Wainwright. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, November 1. The stock has “Buy” rating by Cowen & Co on Wednesday, June 14. Wedbush maintained Stemline Therapeutics, Inc. (NASDAQ:STML) rating on Monday, February 6. Wedbush has “Outperform” rating and $11 target. Cowen & Co maintained Stemline Therapeutics, Inc. (NASDAQ:STML) on Friday, June 23 with “Buy” rating. The firm earned “Buy” rating on Wednesday, August 9 by H.C. Wainwright.

Anthem, Inc., through its subsidiaries, operates as a health benefits firm in the United States. The company has market cap of $60.17 billion. It operates through three divisions: Commercial and Specialty Business, Government Business, and Other. It has a 21.16 P/E ratio. The firm offers a spectrum of network managed care health benefit plans to large and small employer, individual, Medicaid, and Medicare markets.